Skip to main content
< Back to news
The use of fluorescent dyes –compounds joined by target molecules of biomedical interest- is opening new barriers in the techniques of bioimaging and biomedical data processing (Image: FBG).

A team of UB and PCB takes part in the licence of a new technology of fluorescent dyes of biomedical interest

A new article published in the journal Nature Protocols describes the new technology to develop a series of activable fluorophores that enable the peptide molecular labelling and improve cell-live imaging. The new study has the participation of the teams led by Rodolfo Lavilla, from the Faculty of Pharmacy and Food Sciences of the University of Barcelona and the Barcelona Science Park (PCB), and Marc Vendrell, from the Edinburgh Medical School (Scotland).    


This new biomedical major progress is also the center of the licence agreement that has been now signed by the company Cambridge Research Biochemicals (CRB) –with more than thirty-seven years of experience supplying reagents for research- and Edinburgh Innovations, the commercialization arm of the University of Edinburgh, which leads the activities on this innovation transfer. 

This new technology, which is specially focused on the detection of bacterial infections caused by the pathogen fungus Aspergillus fumigatus, will help expanding the catalogue of fluorogenic labelled antimicrobial peptides and will improve the design of future techniques for clinical diagnosis based on these fluorescent dyes.

The participation of the UB experts in applying the patent that protects the new licenced methodology has been managed by Bosch i Gimpera Foundation (FBG), located at the Barcelona Science Park.